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Free radical-mediated damage to macromolecules and the resulting oxidative modification of different cellular components
are a common feature of aging, and this process becomes much more pronounced in age-associated pathologies, including
Alzheimer disease (AD). In particular, proteins are particularly sensitive to oxidative stress-induced damage and these irreversible
modifications lead to the alteration of protein structure and function. In order to maintain cell homeostasis, these oxidized/damaged
proteins have to be removed in order to prevent their toxic accumulation. It is generally accepted that the age-related accumulation
of “aberrant” proteins results from both the increased occurrence of damage and the decreased efficiency of degradative systems.
One of the most important cellular proteolytic systems responsible for the removal of oxidized proteins in the cytosol and in the
nucleus is the proteasomal system. Several studies have demonstrated the impairment of the proteasome in AD thus suggesting a
direct link between accumulation of oxidized/misfolded proteins and reduction of this clearance system. In this review we discuss
the impairment of the proteasome system as a consequence of oxidative stress and how this contributes to AD neuropathology.
Further, we focus the attention on the oxidative modifications of a key component of the ubiquitin-proteasome pathway, UCHL1,
which lead to the impairment of its activity.

1. Introduction
The physiological aging process and age-related diseases
share many common features among which are accumulations of oxidative damage, impaired mitochondrial activity,
and reduced efficiency of clearance systems among others.
In particular, the reduced activity of the “quality control
system” (PQC), including the ubiquitin-proteasome system,
autophagy, and other intracellular proteolytic enzymes, leads
to the accumulation of oxidized/unfolded proteins that may
contribute to neuronal loss. Deposits of aggregated, misfolded, and oxidized proteins accumulate normally over the
lifespan in cells and tissues and enormously increase in
neurodegenerative diseases [1]. Insoluble aggregates can be

formed as a result of covalent cross-links among peptide
chains, as in the case of amyloid-𝛽-peptide (A𝛽) in Alzheimer
disease (AD), 𝛼-synuclein in Parkinson disease (PD), huntingtin in Huntington disease (HD), and SOD1 in amyotrophic
lateral sclerosis (ALS).
Oxidative modification of a protein represents one of
the major causes of its increased susceptibility to aggregate. Indeed, proteins are sensitive to oxidative stressinduced chemical modifications, undergoing several structural changes that are not always correctly recognized by
the proteasome, thus generating impaired protein function. The balance between functional proteins, present in
young/healthy cells, and damaged or altered proteins, present
at higher concentration in aged/diseased cells, depends
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mainly on their modification and turnover [2]. It is generally
accepted that the age-related accumulation of “aberrant”
proteins results from both the increased occurrence of
damage and the decreased efficiency of degradative systems.
Clearance of oxidatively modified proteins most often occurs
through the proteasome system. The proteasome is the principal pathway to remove senescent and damaged proteins,
and intact proteasome function is essential to preserve cellular homeostasis during oxidative stress conditions [3]. The
age-related impairment of proteasome function in different
cell types and organs has been widely demonstrated [4]. Such
a decline of proteasome activity would therefore be expected
to promote the accumulation of oxidized proteins with age.
The reduced activity of the proteasome and other intracellular
proteolytic machineries also has significant implications in
the development of neurodegenerative diseases [4, 5].
What is the picture if oxidative stress targets members
of the PQC? A number of studies suggest that oxidative
stress can target the proteasome and impair its ability to correctly degrade oxidized proteins (reviewed in [6]). Further,
ubiquitin-immunopositive inclusion bodies are commonly
detected in the brain of patients suffering neurodegenerative
diseases possibly as a result of impaired proteasome activity
[4]. If from one side low levels of ROS are able to activate the
expression of inducible proteasome subunits, at increasing
ROS concentrations the proteasome subunits are susceptible
to undergoing oxidative modifications [7], which ultimately
result in impaired proteasome function. In addition, nondegradable protein aggregates and cross-linked proteins are
able to bind to the proteasome, which makes the degradation
of other misfolded and damaged proteins less efficient.
Intriguingly, recent studies proposed the impairment of
proteasome activates autophagy, which might be a compensatory mechanism allowing eliminating ubiquitin-proteasome system (UPS) substrates [8, 9]. Indeed, treatment of
both cells and mice with rapamycin, to induce autophagy, was
able to protect against cell death caused by proteasome inhibition [10] and to protect against genetic loss of proteasome
activity in Drosophila [8]. However, the exact mechanisms
of the cross-talk between proteasome and autophagy are
still not well understood. Among proposed mechanisms
the activation of endoplasmic reticulum (ER) stress, due to
the accumulation of misfolded proteins that leads to the
induction of the unfolded protein response (UPR), is an
interesting candidate. These different mechanisms may not be
mutually exclusive and may also be of different importance in
different cell types or at different time-points after the proteasome is inhibited [11].
In this review, we focus attention on the impairment
of the proteasome system as a consequence of oxidative
stress and how this impairment contributes to neurodegeneration. We suggest that reduced protein turnover may be
caused by the selective oxidative damage of members of the
proteasomal system that once targeted by oxidative stress
are not able to fulfil their protective roles and contribute
to the dysregulation of intracellular protein homeostasis.
The complex interactions of these events in cellular protein
and redox homeostasis in the brain are essential to design
novel therapeutic intervention that may possibly retard the
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development of AD and other neurodegenerative diseases.
AD is a disorder that leads to cognitive, behavioral, and
memory deficits. The hallmarks of AD are the accumulation
of A𝛽 into senile plaques and hyperphosphorylated tau into
neurofibrillary tangles which consequent neuronal loss in
select brain areas involved in learning and memory. A𝛽 is
cleaved from amyloid-𝛽 protein precursor (APP) and comprises a set of 39–43 residue polypeptides that exert a range
of neurotoxic effects that are considered to be important to
the evolution of the pathology.
Ubiquitin-Proteasome System. In the case of protein misfolding and aggregation in cells, the PQC system uses three
main parallel strategies to maintain protein homeostasis. The
misfolded protein may be refolded to recover the protein’s
normal conformation. Different molecular chaperones, such
as heat shock proteins (HSPs), play essential roles in protein
refolding. Alternatively, if the protein cannot be refolded, it is
targeted to the UPS or autophagy programs for degradation
(Figure 1) [12].
The UPS is located in the cytosol and the nucleus, and it
is responsible for the degradation of more than 70–80% of
intracellular proteins. The UPS degrades misfolded/damaged
proteins and removes proteins involved in many cellular
processes, such as signal transduction, cell cycle regulation,
and cell death, and, ultimately, regulates gene transcription
[13, 14].
Most of the proteins targeted for proteasome degradation
are covalently modified by ubiquitin, often in a polyubiquitin
chain. Ubiquitin is an 8.5 kDa protein composed of 76
amino acids. The ubiquitin protein is transcribed from UBB,
ubiquitin C (UBC), RPS27A, and UBCEP2 genes. However,
only the first two genes encode for a polyubiquitin precursor
that is involved in the UPS signaling cascade. The other
genes encode ubiquitin that fuses to ribosomal proteins [15].
Ubiquitin can form polyubiquitin chains at seven lysine
residues on the target protein: Lys-6, Lys-11, Lys-27, Lys-29,
Lys-33, Lys-48, and Lys-63. These chains are formed by the
successive attachment of monomers by an isopeptide bond,
most frequently formed between the side chain of Lys-48
in one ubiquitin and the carboxyl group of the C-terminal
Gly-76 of a neighbouring ubiquitin. Attachment of Lys-48
polyubiquitin chains to lysine residues on a protein results
in at least a 10-fold increase in its degradation rate [16].
Polyubiquitin chains with linkages involving lysine residues
on ubiquitin other than Lys-48 were found to play distinct
roles. Ubiquitin is conjugated through the formation of an
isopeptide bond between the 𝜀-amino group of a lysine
residue of the substrate and the C-terminal carboxylate [17].
First, ubiquitin needs to be activated by an E1 enzyme in
an ATP-dependent reaction, which results in a high-energy
thioester bond between the E1’s active site cysteine and the
carboxyl group of the ubiquitin protein. Then, E2 (ubiquitinconjugating enzyme) receives ubiquitin from E1 and forms a
similar thioester intermediate with ubiquitin. E3 (ubiquitin
ligase) binds both E2 and the substrate and transfers the
ubiquitin to the substrate [18]. The E3 ligase is a pivotal
enzyme in the UPS cascade and is crucial for substrate
specificity. E3 plays a critical role in selecting the substrates,
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Figure 1: Oxidative stress impairs the functionality of the UPS in AD. Under physiological conditions the ubiquitin-proteasome system (UPS)
mediates the clearance of misfolded proteins in order to prevent their toxic accumulation. Indeed, a target protein undergoes multiple cycles
during which it is conjugated with one or more ubiquitin groups leading to mono- or polyubiquitinylated substrates (S). In particular, in
the first step of this cycle, ubiquitin activating enzyme (E1) forms a thioester bond with ubiquitin and this reaction requires ATP as driving
force. Subsequently, the ubiquitin group is transferred to ubiquitin-conjugating enzyme (E2), which works as a scaffold protein favoring
the interaction between ubiquitin ligase (E3) and the target substrate, aimed at allowing the ligase to transfer the ubiquitin group from E2
to the substrate. After a number of cycles promoting the polyubiquitinylation of the substrate, this latter is driven to the proteasome for
its degradation. Polyubiquitinylated substrates also can be targets of the activity of the ubiquitin carboxyterminal hydrolase L1 (UCLH1),
which is highly expressed in neurons and hydrolyses small adducts of ubiquitin to generate the ubiquitin monomer. During the progression
of Alzheimer disease (AD), increased amyloid-beta (A𝛽) production and accumulation favor the augmentation of oxidative stress levels,
which leads to protein oxidative modifications (Ox). Because oxidized proteins are neurotoxic, they would be eliminated through the UPS,
but this does not seem to be the case in AD. Indeed, both A𝛽 and oxidative stress would promote the impairment of the UPS and the
consequent accumulation of polyubiquitinylated proteins, which are visible as aggregates in AD brain. Arrows, promotion; lines, inhibition.
Black, physiological conditions; red, pathological conditions.

and the regulation of either its catalytic activity or substrate
interaction properties is important for the UPS signaling
pathway. E3 ligase enzymes can be grouped into two classes:
those that are homologous to the E6-AP carboxyl terminus
(HECT) and the gene RING ligases. The two classes differ
not only in their structure but also in the way they catalyze
the last step of ubiquitinylation. The HECT ligases accept the
activated ubiquitin from an E2 enzyme on a cysteine residue
in the active domain and then transfer it to the substrate,
whereas the RING ligases act as scaffold proteins by bringing
together an E2 conjugating enzyme and the substrate [19].
The F-box and leucine rich repeat protein 2 (FBL2) is another
component of the SCF (Skp1–Cullin1–F-box protein) E3
ubiquitin ligase complex that has been found to be decreased
in the brains of AD patients [20]. Interestingly, the Watanabe
group demonstrated that FBL2 impacts APP metabolism by
interacting with APP to modulate APP ubiquitinylation. In

detail, FBL2-mediated ubiquitinylation of APP inhibits its
endocytosis [21].
In some circumstances, a fourth ubiquitinylation enzyme,
known as the ubiquitin chain elongation factor E4, is necessary, together with the E1, E2, and E3 enzymes, to extend a
polyubiquitin chain [22]. This cascade results in ubiquitinylation of the target protein. A polyubiquitin chain of at least
four ubiquitin moieties is necessary for efficient translocation
of the substrate to the proteasome [23]. Monoubiquitinylation is not associated with protein degradation, but with
endocytosis, protein sorting, DNA damage response, and
epigenetics [24–26].
Ubiquitinylation is a reversible posttranslational modification, and a family of proteases, the deubiquitinylating
enzymes (DUBs), can remove ubiquitin from substrates,
thereby regulating the ubiquitinylation process and recycling ubiquitin. The recycling of ubiquitin is critical for the

4
brain, which has a fixed amount of ubiquitin. DUBs are
highly specific and have been grouped into five subfamilies:
ubiquitin carboxyl-terminal hydrolases (UCH), ubiquitinspecific proteases (USP), ovarian tumor- (OTU-) like proteases, JAB1/MPN/Mov34 (JAMM/MPN) metalloproteases,
and the Machado-Jakob disease proteases [27]. The state of
substrate ubiquitinylation depends on the balance between
ubiquitinylating and deubiquitinylating enzymes acting on
a protein. Thus, cells developed a highly dynamic strategy
based on a switch-on/switch-off type of mechanism that
responds promptly to cellular requirements for proteolysis
by the UPS. Ubiquitinylated substrates with a Lys-48-linked
ubiquitin chain of sufficient length are targeted to the 26S
proteasome for degradation.
The 26S proteasome is composed of a 20S catalytic core
and two 19S regulatory caps on both ends of the 20S core.
The 20S proteasome contains four stacked rings that form
a barrel-shaped moiety with a central cavity [28]. These
stacked rings include two noncatalytic outer rings called
𝛼-rings and two catalytic inner rings called 𝛽-rings. Three
proteolytic activities are confined to the 𝛽-rings including
chymotrypsin-like, caspase-like, and trypsin-like protease
activities [19]. The 19S caps contain at least 18 subunits, with
a base composed of six ATPases that exert a chaperone-like
activity and a lid composed of eight subunits that recognize
the polyubiquitin signals. The 19S proteasome binds and
unfolds ubiquitinylated proteins and opens the entry gate of
the 20S proteasome to allow protein in the central cavity [19].
Oxidation of a protein induces several reversible or
irreversible alterations, including amino acid modification,
fragmentation, or aggregation and causes increased susceptibility of the modified proteins towards proteolysis [29, 30]. It
has been suggested that the oxidation of proteins causes the
exposure of hydrophobic moieties to the surface via partial
unfolding which are targeted by proteasome [31–33]. While
the 26S proteasome degrades polyubiquitinylated proteins,
the 20S proteasome by itself seems to be sufficient to degrade
nonubiquitinylated oxidatively modified proteins in an ATPindependent manner; however, the exact mechanism is still
unclear [13, 18, 19].
Deubiquitinylating Enzymes: UCHL1. DUBs function in the
processing of ubiquitin precursors and ubiquitin adducts
[34]. DUBs belong to a protease superfamily, and about 100
members are expressed in humans [35, 36]. The UCH class
of DUBs consists of four proteins (Bap1, UCHL1, UCHL3,
and UCHL5), which all have a conserved catalytic domain
(UCH-domain) consisting of about 230 amino acids [35,
36]. Ubiquitin carboxyterminal hydrolase L1 (UCHL1) is
a 223-amino-acid protein encoded by 9 exons [37]. The
catalytic area of UCHL1 has a loop positioned over the
active site, which limits the size of ubiquitin adducts that
can be processed by it to small peptides [38]. UCHL1 is
proposed to function largely by maintaining a stable pool
of monoubiquitin for use in ubiquitinylation reactions, as
showed in Figure 1 [27, 35]. Newly translated ubiquitin
contains amino acids following the terminal glycine residue
that is used for isopeptide bond formation. UCHL1 can cleave
off these additional amino acids in order to expose the final
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glycine of ubiquitin for conjugation. UCHL1 can also help
maintain the monoubiquitin pool by reversing accidental
modifications that can form during ubiquitin activation [39].
Due to its specificity, UCHL1 does not remove ubiquitin from
all proteins. It is this selectivity that offers unique advantages
for drug discovery efforts. UCHL1 is also involved in the
cotranslational processing of proubiquitin and ribosomal
proteins translated as ubiquitin fusions [37]. In addition,
UCHL1 can form dimers, whose form seems to act as another
enzymatic activity in UCHL1, the ubiquitin ligase activity
[40]. In the dimeric form, UCHL1 ligase activity produces
Lys-63-linked ubiquitin chains to its substrates. In contrast
to the well-recognized ubiquitinylation pathway with E1, E2,
and E3 ligases, UCHL1 does not require ATP as a notable
characteristic of this ligase. Interestingly, when they are
polyubiquitinylated via Lys-63 of ubiquitin, the substrates
escape from UPS-dependent protein degradation leading to
their stabilization. The dual function of both addition and
removal of monoubiquitin sets UCHL1 apart from other
DUBs and makes it a special target for proper UPS function
[41].
UCHL1 is among the most abundant proteins in the brain
reaching 1-2% of total brain lysate and regulating the timing
and the pattern of ubiquitinylation of brain proteins [37]. It is
also one of the main enzymes that play a role in maintaining
free ubiquitin levels in neurons [20, 21]. UCHL1 is also present
in the peripheral nervous system, such as the dorsal root
ganglion and trigeminal ganglion neurons [36]. UCHL1 is
involved in synaptic activities and a reduction in UCHL1
function has been linked to neurodegenerative diseases [36,
42]. UCHL1 is also studied due to its association with various
malignancies, including colorectal, breast, prostate, and lung
cancers [43]. The UCHL1 gene is known as PARK5, and its
mutations are associated with Parkinson disease [42]; indeed
the I93M mutation shows severely diminished hydrolase
activity and lower E3 activity, while the S18Y mutant has
greater hydrolase activity but lower E3 activity than WT
[37, 44]. Further, deletion of one of the active site residues of
the UCHL1 gene is associated with gracile axonal dystrophy
and leads to elevated oxidative damage in the brain [45].
UCHL1 is susceptible to oxidative damage and when
this occurs it has aberrant functions analogous to mutated
UCHL1 [46, 47]. Moreover, aberrant UCHL1 is able to
interact with Lamp2a, Hsc70, and Hsp90 thus inhibiting
chaperone mediated autophagy- (CMA-) dependent degradation and causing the accumulation of CMA substrates (e.g.,
𝛼-synuclein) [48, 49].

2. Impairment of Ubiquitin-Proteasome
System in Alzheimer Disease
The first observations about increased ubiquitin accumulation in specific structures characterizing human AD brain
were showed about 30 years earlier. Indeed, ubiquitin was
found to be covalently associated with the insoluble material
of NFT and SP [50–52], thus suggesting that something in
the degradative systems did not work properly. However, the
presence of ubiquitin in abnormal aggregates was not associated with the subsequent proteolytic step [51]. Specifically,
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A𝛽 inhibited the chymotrypsin-like activity but had no effect
on the proteolytic activity of the protease chymotrypsin,
suggesting that A𝛽 did not interact with the active site of
the proteasome subunit [53]. Reduced chymotrypsin-like and
peptidyl-glutamyl peptide-hydrolysing activity was found in
AD brain [54].
The role of A𝛽 peptides in those processes was further
investigated by Oh et al., who demonstrated that increased
A𝛽 levels paralleled decreased chymotrypsin-like activity of
the 26S proteasome in cortex and hippocampus of Tg2576
mice, a well characterized AD animal model that ubiquitously
expressed Swedish mutant amyloid precursor protein (APPswe) [55]. These results were also confirmed in B103 cells, a
rat neuroblastoma cell line, in which A𝛽 treatment led to the
inhibition of the proteasome activity [55], even though the
mechanism involved in the inhibition of proteasome induced
by A𝛽 is still unclear.
Because the effects mediated by A𝛽 can be dependent
on its aggregation state, Cecarini and colleagues analyzed
the impact of nonfibrillar, oligomeric, and fibrillar forms of
A𝛽 on the proteasome activities in both the isolated 20S
proteasome and SH-SY5Y cells [56]. They found a significant
reduction only in the chymotrypsin-like activity in isolated
20S proteasome preparations treated with A𝛽, independent
of the aggregation state of this peptide [56]. Rather, these
investigators showed a general decrease of the proteasome
functionality especially upon treatment with the oligomeric
and fibrillar forms in SH-SY5Y cells [56]. In fact, comparing
these assays with that obtained using purified proteasomes,
the tested activities were all significantly reduced. The marked
decrease in proteasome functionality was also confirmed by
the enhancement in the levels of ubiquitin protein conjugates.
These results agree with the proposed toxic role of A𝛽,
possibly independent of its aggregation state.
While, on one hand, A𝛽 could be directly responsible for
the proteasome impairment as cited above, on the other hand,
the impairment of other members belonging to the UPS
could also favor A𝛽 accumulation. In light of these findings
A𝛽 is a part of a vicious cycle whereby its accumulation
promotes the proteasome impairment responsible for further
accumulation of A𝛽-proteins.
Interestingly, Rosen et al. reported that the overexpression of the ubiquitin E3 ligase Parkin, which was found
reduced in human AD brain, greatly decreased the levels of
intracellular A𝛽-42 in neurons [57]. This effect was abrogated
by proteasome inhibition [57]. In addition, these researchers
reported that intracellular A𝛽-42 accumulation decreased
cell viability and proteasome activity, while Parkin reversed
both effects [57]. The importance of Parkin has been further
highlighted in a subsequent study, where the overexpression
of Parkin in APP/PS1 transgenic mice restored activitydependent synaptic plasticity and rescued behavioral abnormalities [58].
Similarly, the ubiquitin ligase HRD1, which normally
promotes APP ubiquitinylation and degradation resulting
in decreased generation of A𝛽, was found impaired in
AD brain [59]. Indeed, suppression of HRD1 induced APP
accumulation and increased production of A𝛽 in vitro,
resulting in apoptosis [59]. In addition, Zhang et al. found
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that inhibition UCHL1 significantly increased 𝛽-secretase
1 (BACE1) protein level in vitro [60]. BACE1 half-life was
reduced in cells overexpressing UCHL1 and decreased APP
C-terminal fragment C99 and A𝛽 levels were observed [60].
Taken together, the impairment of members of the UPS
different from the 26S proteasome itself, such as Parkin,
HRD1, and UCHL1, may affect APP processing and A𝛽
production.
2.1. Oxidative Damage to UPS. Among the factors contributing to the impairment of UPS in AD, augmentation of the
oxidative/nitrosative stress levels was proposed as conceivable causative effect [61]. Indeed, levels of oxidized proteins
in AD are associated with loss of the activity of the 20S proteasome, which, as noted above, represents a major enzyme
for the degradation of oxidized proteins [54, 62–64]. Interestingly, studies from the Davies and Grune groups showed that
moderately oxidized proteins are preferentially recognized
and degraded by the proteasome; however, severely oxidized
proteins cannot be easily degraded and, instead, inhibit
the proteasome [3, 65]. Further, studies have shown that
prolonged oxidized proteins are more resistant to degradation
by 20S proteasomes [66, 67]. Therefore, overloading the UPS
by undegradable substrates, mutations, or oxidative damage
may lead to the accumulation of abnormal proteins and to the
selective degeneration of neurons.
In that context both the Butterfield group [46, 68] and
others [69] demonstrated that UCLH1 is oxidatively modified
in AD, establishing a link between the effect of oxidative
stress on protein and the proteasomal dysfunction. Similarly,
Saito et al. showed that HRD1 protein was insolubilized by
oxidative stress but not by other AD-related molecules and
stressors, such as amyloid-𝛽, tau, and ER stress. Furthermore,
these authors raised the possibility that modifications of
HRD1 by 4-hydroxy-2-nonenal, decreased HRD1 protein
solubility leading to the accumulation of HRD1 into the
aggresome [70]. In addition, the identification of oxidative
stress-induced modification of the heat shock cognate 71
seems to underlie the essential link between the folding and
degradation machineries that once impaired by oxidative
damage become critical for cell viability [71].
Nitric oxide- (NO-) induced S-nitrosylation of the protein disulphide isomerase (PDI) was proposed to have a
role relating protein misfolding to neurodegeneration [72].
Indeed, S-nitrosylation inhibited PDI enzymatic activity and
led to the accumulation of polyubiquitinylated proteins [72,
73]. S-nitrosylation also abrogated PDI-mediated attenuation
of neuronal cell death triggered by ER stress, misfolded
proteins, or proteasome inhibition [72]. Thus, PDI prevents
neurotoxicity associated with ER stress and protein misfolding, but NO blocks this protective effect in neurodegenerative
disorders through the S-nitrosylation of PDI [72].
Cecarini et al. also demonstrated that despite lack of
differences in the amount of proteasome complex isolated
from control, MCI, and AD brains, a large impairment in
proteasome-mediated degradation of an oxidized protein was
observed in MCI and AD subjects [74]. The impairment
was associated with the elevation of proteasome oxidative
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modifications such as protein carbonyls, 4-hydroxynonenalconjugation, and neuroprostane-conjugation [74]. Intriguingly, the incubation of proteasome complexes with a reducing agent fully restored proteasome-mediated protein degradation in both MCI and AD samples, thus supporting a role
for oxidative stress in promoting proteasome inactivation
[74].
2.2. Mutant Ubiquitin UBB+1 . Together with A𝛽 and oxidative/nitrosative stress, a mutant form of ubiquitin, deriving
from a molecular misreading of the ubiquitin gene and
termed UBB+1 , was found to be selectively expressed in the
brains of AD patients [75] and was reported to impair the proteasome activity in vitro [76].
Indeed, Lam and colleagues showed for the first time that
(i) UBB+1 is polyubiquitinylated (UBB+1 -polyubiquitin); (ii)
UBB+1 -polyubiquitin was strongly resistant to disassembly
and accumulates in cells; and (iii) UBB+1 -polyubiquitin
inhibited proteasomal activity, thus providing a likely mechanism of toxicity [76]. In accordance with these observations,
overexpression of UBB+1 in neuroblastoma cells significantly
induced nuclear fragmentation and cell death [77].
The complex nature of UBB+1 interactions was illustrated
by the finding that on one hand the induction of UBB+1
expression in SH-SY5Y cells caused proteasome inhibition,
while on the other hand UBB+1 also induced the expression of
heat shock proteins, which conferred a subsequent resistance
to tertbutyl hydroperoxide-mediated oxidative stress. Indeed,
these authors concluded that although UBB+1 -expressing
cells have a compromised ubiquitin-proteasome system,
these cells are protected against oxidative stress conditions.
However, which one of these two effects is prevalent does
not emerge from the study and requires further investigations
[78].
From the point of view of the mechanisms underlying UBB+1 -induced neurotoxicity, an ubiquitin-conjugating
enzyme, E2-25K/Hip-2, which was found to be upregulated
in the neurons exposed to A𝛽42 and in the brain of AD
patients, was proposed to have a role [76, 79]. E2-25K/Hip2 seems to function both as an E2 ubiquitin-conjugating
enzyme like other E2 proteins and as an unusual ubiquitin
ligase to produce diubiquitin and unanchored polyubiquitin
chains without any E3 ligase [80]. E2-25K/Hip-2 was shown
to reduce proteasome activity [79]. Rather, E2-25K/Hip-2
was found to play a major role in A𝛽 neurotoxicity by
promoting the polyubiquitinylation of UBB+1 , which leads to
proteasome inactivation [79].
However, a protective role for UBB+1 was also reported.
By using a triple transgenic mouse (APP/PS1/UBB+1 )
obtained by crossing UBB+1 and APP/PS1 transgenic mice,
van Tijn and colleagues showed a transient and significant
decrease in A𝛽 deposition and soluble A𝛽 1–42 levels in APP/
PS1/UBB+1 transgenic mice compared to APP/PS1 mice at 6
months of age [81].
2.3. Dysfunction of UPS and Tau Aggregation. While A𝛽
was mainly found to both directly and indirectly trigger
the inhibition of proteasome activity, probably the most
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investigated target in terms of proteins aggregation following
proteasome inhibition in AD is tau. Studies in AD brain
demonstrated that phosphorylated tau accumulated on both
sides of the synapse, thus showing synaptic enrichment of
this protein when compared with the cytoplasm [82]. The
accumulation of p-tau at the synapse mirrors the accumulation of ubiquitinylated proteins in the same fraction, as well
as the accumulation of proteasomes and related chaperones,
consistent with the notion that tau aggregates are associated
with impaired proteolysis mediated by the UPS [82].
Zhang et al. in 2005 reported for the first time that tau,
both phosphorylated and nonphosphorylated, is degraded
by the 26S proteasome in an ubiquitin- and ATP-dependent
manner, suggesting that defect in the UPS would promote tau
accumulation [83].
In agreement with the above, Cripps et al. reported
that soluble paired helical filaments (PHF) of tau protein
are ubiquitinylated at their microtubule-binding domain
(at residues Lys-254, Lys-311, and Lys-353), suggesting that
ubiquitinylation of PHF-tau may be an earlier pathological
event and that ubiquitinylation could play a regulatory role in
modulating the integrity of microtubules during the course
of AD [84]. Through the use of tandem mass spectrometry,
the same group highlighted that PHF-tau is modified by
three polyubiquitin linkages at Lys-6, Lys-11, and Lys-48
[84]. Among these, Lys-48-linked polyubiquitinylation is the
primary form of polyubiquitinylation with a minor portion of
ubiquitin linked at Lys-6 and Lys-11 [84]. Because modification by Lys-48-linked polyubiquitin chains is known to serve
as the essential means of targeting proteins for degradation by
the ubiquitin-proteasome system, a failure of the UPS could
play a role in tau accumulation in AD [84].
The role of PHF-tau was further highlighted by Gillardon
et al., who proposed that the reduced peptidase activity
observed in AD brain extracts is not an intrinsic property of
the 20S proteasome but may be resulting from the presence
of endogenous inhibitory proteins or substrates, for example,
PHF-tau [85]. Indeed, these investigators found that proteasome activity was increased upon purification from AD brain
[85], while the presence of cytosolic proteins, which had been
removed during the purification process, led to proteasome
inhibition [85].
Quite recently, HRD1 ubiquitin ligase, previously
reported to favor APP degradation [59], was also identified
as a negative regulator of tau phosphorylation in AD [86]. In
fact, Shen et al. reported that HRD1 interacts with tau and
promotes the degradation of both dephosphorylated and
phosphorylated tau through the 26S proteasome [86].
An intriguing aspect about proteasome-mediated degradation of tau protein was the discovery that hyperphosphorylation of tau diminishes its recognition by the proteasome [87], thus questioning which form of proteasome is
responsible for tau degradation: the classical ATP/ubiquitindependent 26S proteasome pathway and/or a 20S proteasome
pathway not requiring ubiquitin or ATP? Indeed, the Poppek
group reported that the ATP/ubiquitin-independent 20S
proteasome could degrade tau in vitro [87], while evidence
also exists that, under certain conditions, the tau protein
is polyubiquitinylated and directed to the 26S proteasome
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[83, 84, 88, 89]. Starting from such apparently conflicting
reports, Grune and colleagues demonstrated in vitro that
the normal turnover of the tau protein is catalyzed by the
proteasome in an ATP/ubiquitin-independent manner and
that the 20S proteasome is more important for normal tau
turnover than is the 26S proteasome [90]. This interpretation
seems reasonable, since the tau protein is largely unfolded
and, therefore, should not require ATP for unfolding prior
to degradation [90]. Conversely, under other conditions,
including certain stress situations, the ATP/ubiquitin pathway and the 26S proteasome may be more important [90].
2.4. Role of ATP and Aggregated Proteins. Because ATP
represents the essential driving force for UPS activity links
between mitochondrial impairment and proteasome activity
also have been evaluated. Huang et al. in 2013 demonstrated
that cortical neurons treated with inhibitors of different
elements of the electron transport chain showed a reduction
in ubiquitinylated proteins and E1 activity as well as a
calpain-mediated disassembly of the 26S proteasome [91].
Calpain activation promoted the cleavage of the microtubuleassociated protein tau, leading to its accumulation [91].
Furthermore, all these changes paralleled increased 20S
proteasome levels and activity [91]. The concomitant rise
in the 20S proteasomes, which seem to degrade proteins
in an unregulated and energy-independent manner, in the
short-term may carry out the turnover of randomly unfolded
oxidized proteins [91]. However, if chronic, this process could
lead to neurodegeneration, as regulated protein degradation
by the ubiquitin/proteasome pathway is essential for neuronal
survival [91].
Although polyubiquitin aggregates are evident in AD
brain, the identification of the proteins present in that
structure is still elusive and studies on this are ongoing in
our laboratories. Indeed, only a few examples emerge from
the literature aimed at strengthening the role of the impaired
UPS response in the progression of AD pathology.
𝛽-Catenin, a member of the Wnt-signaling pathway,
is a multifunctional protein that participates in cadherinmediated cell adhesion and in transcriptional activation
of Wnt target genes involved in development [92]. In the
absence of a Wnt ligand, 𝛽-catenin is phosphorylated and
is targeted for multiubiquitinylation by 𝛽-Trcp E3 ligase followed by rapid degradation by the 26S proteasome machinery
[92]. Interestingly Ghanevati and Miller demonstrated that
inhibition of the proteasome machinery in neuronal cultures
leads to the progressive accumulation of phospho-𝛽-catenin
protein and formation of scattered, punctate cytoplasmic
inclusions, which ultimately coalesced into a large cytoplasmic aggresome [92].
Striatal-enriched protein tyrosine phosphatase 61
(STEP61), the only isoform of this brain-specific family of
phosphatases expressed in the cortex, localizes to postsynaptic terminals and the endoplasmic reticulum [93]. STEP61
associates with the NMDA receptor (NMDAR) complex,
reduces NMDAR activity, and opposes the induction of LTP
[93] with deleterious effects on cognitive functions. Kurup
and colleagues demonstrated that STEP61 levels are elevated
in aged transgenic AD model mice (Tg2576) and in AD
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brains and that A𝛽 is sufficient to increase STEP61 levels [93].
Increased STEP61 both in mice brain and in A𝛽-treated cells
had been found, thus suggesting an inhibition of the UPS
[93]. The evidence outlined above highlights how a defective
UPS activity is also associated with the accumulation of
proteins, whose activation persists over the time, thus
contributing to cognitive dysfunction in AD.
Studies have demonstrated that proteasome inhibition
may occur also during normal aging [94, 95], which definitively represents one of the main risk factors for AD
development. Thus, proteasome dysfunction together with
other unknown mechanisms could contribute to protein
aggregation throughout the lifetime. In that picture, the
analysis of four molecular chaperones (Grp78, Grp94, PDI,
and calnexin) revealed a marked decrease in aged rat hippocampus compared to young controls [96]. In addition, the
levels of ubiquitinylated proteins were increased [96]. Thus,
an age-related decrease in chaperone expression, together
with an age-related decrease in proteasome activity [94,
97], conceivably could account for the increased content of
ubiquitinylated proteins. Indeed, aged rats could be more
predisposed to the formation of protein aggregates that in
turn disrupt cellular functions and provide nucleation sites
for the aggregation of other proteins. This scenario, together
with environmental, genetic, and other unknown factors,
could predispose development of age-related neurodegenerative disorders, such as AD.
2.5. Oxidative Modifications of UCHL1 in Alzheimer Disease.
Protein ubiquitinylation can be regulated by modulating
the enzyme levels or activity of deubiquitinylating enzymes
such as UCHL1. This is an important mechanism for regulating a variety of cellular processes, including synaptic
function, protein degradation, and neuronal apoptosis [98].
Thus, dysfunction of UCHL1 has been directly implicated in
neurodegenerative diseases, such as AD. Of special interest
is the finding that UCHL1 is involved, by maintenance of
ubiquitinylation/deubiquitinylation machinery, in memory
formation. In particular, the first study on UCHL1 was
conducted in Aplysia, a model system used to investigate
neuronal events associated with learning. Further studies
confirmed the relevance of UCHL1 in synaptic function [99,
100].
Knockout mice for UCHL1 showed decreasing acetylcholine release from the synaptic terminal, which could be
due to perturbed ubiquitin-dependent pathways as a result
of decreased ubiquitin recycling. This reduction in content
release is accompanied by hindered synaptic plasticity, nerve
terminal retraction, and axonal degeneration [100]. In line
with these findings, Zhang et al. showed that the gracile
axonal dystrophy (gad) mutant mouse, which presents a
deletion within the gene encoding for UCHL1, displays
brain axonal degeneration [101]. These data suggest that the
lower expression of UCHL1 may be partially responsible
for cognitive impairment and Alzheimer pathophysiology.
To consolidate these results and the involvement of UCHL1
in AD, Zhang and coworkers administered UCHL1 by
intracranial injection of UCHL1-expressing rAAV into the
hippocampus of the transgenic mice. Increased expression of
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the enzyme reduced A𝛽 production, inhibited neuritic plaque
formation, and improved memory deficits [101]. A second
study on a double transgenic mouse model of AD further
supports this evidence. These mice showed cognitive defects
such as inhibition of LTP, and the protein level of UCHL1 was
significantly decreased in hippocampus [102]. Transduction
to hippocampal slices of UCHL1 fused to the domain of
HIV-transactivator protein (TAT) significantly restored A𝛽induced inhibition of LTP and also reestablishes normal UCH
activity, basal neurotransmission, and synaptic plasticity and
improves associative memory in APP/PS1 mice [102]. Interestingly, exogenous UCHL1 ameliorated 𝛽-amyloid-induced
synaptic and memory dysfunction in an AD mouse model.
UCHL1 is important at synapses and suggests that increased
UCHL1 activity could counteract certain symptoms in AD.
Furthermore, data from the Butterfield group demonstrated that UCHL1 reduced activity was due to specific
oxidative modifications, which can block its normal functioning. In fact an increased amount of oxidatively modified
UCHL1 was found in the brains of AD patients, compared
to normal brains [46, 103]. Proteomics analyses showed that
UCHL1 is a major target of oxidative damage in frontal
cortex of AD subjects [46], which is extensively modified
by carbonyl formation, methionine oxidation, and cysteine
oxidation [69]. Moreover, in the neurofibrillary tangles of
AD patients a deposition of proteins modified by HNE, a
product of lipid peroxidation, was reported [104]. To support
this view, in vitro data showed that addition of HNE induced
the HNE modification of recombinant UCHL1 [105]. UCHL1
immunostaining displayed a prominent association between
the enzyme and neurofibrillary tangles and the level of soluble
UCHL1 protein is inversely proportional to the number of
tangles in AD brains [69]. Potentially due to its sequestration
in neurofibrillary tangles, soluble UCHL1 levels are decreased
in postmortem AD brains [37]. In inherited AD, UCHL1 was
oxidatively damaged [106].
It is well known that oxidative stress causes protein
modification, which can result in altered protein function. A
reduction in the levels of functional UCHL1 was speculated
to contribute to the pathogenesis of AD. In light of this
evidence, the hydrolase activity of HNE-modified UCHL1
was reduced to about 40–80% of nonmodified UCHL1 and
was inversely correlated with the degree of modification [46,
69]. A recent study from our laboratory observed that UCHL1
is a target of oxidative damage also in Down Syndrome
(DS) brains [47]. DS presents many common features of AD,
such as early deposition of A𝛽 plaques and, above 40 years
of age, development of AD-like dementia [107]. Similar to
what is found in AD, UCHL1 enzyme activity was decreased
about 30% in DS brain compared to controls [47]. These
two events, oxidation and decreased activity of UCHL1, can
be correlated in DS subjects similar to AD. Moreover, in
DS subjects UCHL1 impairment is an early event occurring
before clinical manifestation of dementia, thus contributing
to neurodegenerative phenomena.
Overall these results discussed in this review show that
in different animal models and human specimens aberrant UCHL1 activity is caused by oxidative modifications
that in turn might lead to dysfunction of the neuronal
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ubiquitinylation/deubiquitinylation machinery, causing synaptic deterioration and neuronal degeneration in AD (Figure 1). Moreover, overexpression of UCHL1 delays AD
progression in mouse models, and UCHL1 gene therapy,
to overexpress UCHL1, in the brain potentially could be a
promising disease-modifying strategy for AD therapeutics.

3. Conclusions
A close connection between protein clearance network
dysfunction and mechanisms of neurodegeneration is well
documented. Potentially toxic oxidized and aggregated proteins harm neuronal cells once these are deprived of the
cytoprotective functions of the PQC. In this scenario, a
crucial role is played by oxidative stress that contributes to
the buildup of oxidized/misfolded proteins. Concomitantly,
oxidative stress targets members of the PQC, such as proteasome subunits and UCHL1, thus leading to its reduced ability
to remove damaged/dysfunctional proteins. Taken together,
these findings highlight that induction/protection of protein
degradative system may represent an efficient therapeutic
strategy for AD, as well as other neurodegenerative diseases.
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